Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis - A single institution experience

Journal of B.U.ON.

Volumn 18, Issue 3, 2013, Pages 641-646

  Cvetanovic, Ana ^a   Vrbic, S ^a,b   Filipovic, S ^a,b   Pejcic, I ^a,b   Milenkovic, D ^a   Zivkovic, N ^b  

^a Clinical Centre Nis   (Serbia)

^b UNIVERSITY OF NI   (Serbia)

Author keywords

Bevacizumab; Metastatic colorectal cancer; Oxaliplatin based treatment; Preoperative treatment

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MELENA; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGRESSION FREE SURVIVAL; RASH; THROMBOCYTOPENIA; URTICARIA; VERTIGO; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SAFETY;

EID: 84885785688     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
2. Kozloff M, Ulcickas Yood M, Berlin J et al. Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. The Oncologist 2009;14:862-870.
3. Kesmodel S, Ellis L, Lin E et al. Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases. J Clin Oncol 2008; 26:5254-5260.
4. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer. J Clin Oncol 2008; 26:1830-1835.
5. Hochster H, Hart L, Ramanathan R et al. Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study. J Clin Oncol 2008;26:3523-3529.
6. Okines A, del Puerto O, Cunningham D, Chau I, Van Cutsem E, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101:1033-1038.
7. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009;20:1842-1847.
8. Berry S, Cunningham D, Michael M et al. Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and fluoropyrimidines for mCRC: First BEAT. Eur J Cancer Suppl 2007;5:241(abstr 3020).
9. Tobelem G. VEGF: A key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Target Oncol 2007;2:153-164.
10. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544. (Pubitemid 46733080)
11. Hedrick E, Kozloff M, Hainsworth J et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BriTE). J Clin Oncol 2006; 24: 18s (abstr 3536).
12. Wong R, Cunningham D, Barbachano Y et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011;22:2042-2048.
13. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
14. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
15. Saltz L, Clarke S, Diaz-Rubio E et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. J Clin Oncol 2008;26:2013-2019.
16. Nordlinger B, Sorbye H, Glimelius B. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-1016. (Pubitemid 351392040)
17. Bismuth H, Adam R, Levi F et al. Resection of unresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-520.
18. Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for unresectable colorectal liver metastases. Ann Surg Oncol 2001;8:347-353. (Pubitemid 32422861)
19. René A, Delvart V, Pascal G et al. Rescue Surgery for Unresectable Colorectal Liver Metastases Down-staged by Chemotherapy. Ann Surg 2004; 240: 644-658. (Pubitemid 39281287)
20. Quenet F, Nordlinger B, Rivoire M et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. Proc Am Soc Clin Oncol 2004; 23: 3613(abstr).
21. Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933-939. (Pubitemid 39004350)
22. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669. (Pubitemid 29342371)
23. Gruenberger T, Schuell B, Kornek G, Scheithauer W. Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases:Impact on magnitude of liver resection and survival. Proc Am Soc Clin Oncol 2004; 23:3598 (abstr).
24. Willett C, Duda D, Boucher Y et al. Phase I/II study of neoadjuvant bevacizumab with radiation therapy and 5-fluorouracil in patients with rectal cancer: Initial resuits. ASCO Annu Meet Proceed, Part I. J Clin Oncol 2007;25:4041(abstr).
25. Czito BG, Bendell JC, Willett CG et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 2007;68:472-478. (Pubitemid 46694189)
26. Crane C, Eng C, Feig B et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010;76:824-830.
27. Brouquet A, Vauthey JN, Contreras CM et al. Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: A study of 112 patients with limited lung metastatic disease. J Am Coll Surg 2011;213:62-69.
28. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 3002; 14 (Suppl 2): ii13-ii16.